Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy Journal Article

   


Authors: Glass, J. L.; Derkach, A.; Hilden, P.; King, A.; Seo, S. K.; Ahr, K.; Kishtagari, A.; Levine, R. L.; Tallman, M. S.; Douer, D.
Article Title: Arsenic trioxide therapy predisposes to herpes zoster reactivation despite minimally myelosuppressive therapy
Abstract: Acute Promyelocytic Leukemia (APL) is a unique subtype of acute myeloid leukemia that is highly responsive to minimally myelosuppressive therapy with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). We and others have observed a higher than expected incidence of herpes zoster reactivation in APL patients treated with ATO. Memorial Sloan Kettering Cancer Center (MSKCC) has been using ATO since 1997 in all relapsed APL patients, and more recently has included it in our front-line APL regimens. Here we present a retrospective analysis of the factors contributing to herpes zoster reactivation among APL patients. © 2021 Elsevier Ltd
Keywords: herpes zoster; arsenic trioxide; acute promyelocytic leukemia
Journal Title: Leukemia Research
Volume: 106
ISSN: 0145-2126
Publisher: Elsevier Ltd  
Date Published: 2021-07-01
Start Page: 106569
Language: English
DOI: 10.1016/j.leukres.2021.106569
PROVIDER: scopus
PUBMED: 33857746
PMCID: PMC8187313
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103950953&doi=10.1016%2fj.leukres.2021.106569&partnerID=40&md5=10ee37e24060498083936ef505336bdc
Notes: Article -- Export Date: 3 May 2021 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Susan Seo
    120 Seo
  2. Martin Stuart Tallman
    649 Tallman
  3. Ross Levine
    776 Levine
  4. Dan Douer
    87 Douer
  5. Patrick Dale Hilden
    108 Hilden
  6. Jacob Lowell Glass
    56 Glass
  7. Amber Courtney King
    32 King
  8. Andriy Derkach
    148 Derkach
Related MSK Work